Similar articles

• [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].

  González-Gay MA, Agudo M. González-Gay MA, et al. Med Clin (Barc). 2010 May 22;134(15):684-5. doi: 10.1016/j.medcli.2009.12.003. Epub 2010 Feb 21. Med Clin (Barc). 2010. PMID: 20176386 Spanish. No abstract available.
• Which TNF inhibitor for rheumatoid arthritis?

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2010 May 17;52(1338):38-9. Med Lett Drugs Ther. 2010. PMID: 20467356 No abstract available.
• Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).

  Iannone F, Ferraccioli G, Gremese E, Lapadula G; Gruppo Italiano di Studio sulle Early Arthritides (GISEA). Iannone F, et al. Ann Rheum Dis. 2014 Jun;73(6):e31. doi: 10.1136/annrheumdis-2013-205011. Epub 2013 Dec 24. Ann Rheum Dis. 2014. PMID: 24368512 No abstract available.
• Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.

  Anderson P, Louie J, Lau A, Broder M. Anderson P, et al. Curr Rheumatol Rep. 2005 Mar;7(1):3-9. doi: 10.1007/s11926-005-0002-2. Curr Rheumatol Rep. 2005. PMID: 15760575 Review. No abstract available.
• [TNF targetting therapy for rheumatoid arthritis].

  Takeuchi T. Takeuchi T. Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1787-94. doi: 10.2169/naika.95.1787. Nihon Naika Gakkai Zasshi. 2006. PMID: 17037316 Review. Japanese. No abstract available.